カテゴリ： 世界, 医療/バイオ, QYResearch

α-1治療の世界市場2023年：増強療法、嚢胞性線維症（CF）、非CF気管支拡張症（NCFB）、糖尿病、その他

■ 英語タイトル：Global Treatments for Alpha-1 Market Research Report 2023

調査会社QYResearch社が発行したリサーチレポート（データ管理コード：QYR23MA8912）■ 発行会社/調査会社：QYResearch
■ 商品コード：QYR23MA8912
■ 発行日：2023年3月
■ 調査対象地域：グローバル
■ 産業分野：医薬品
■ ページ数：85
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後2-3営業日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD2,900 ⇒換算￥440,800見積依頼/購入/質問フォーム
Multi User（5名様閲覧用）USD4,350 ⇒換算￥661,200見積依頼/購入/質問フォーム
Enterprise License（同一法人内共有可）USD5,800 ⇒換算￥881,600見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※QYResearch社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[α-1治療の世界市場2023年：増強療法、嚢胞性線維症（CF）、非CF気管支拡張症（NCFB）、糖尿病、その他]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

当調査資料はα-1治療のグローバル市場について調査・分析し、世界のα-1治療市場概要、市場トレンド、主要企業別競争状況、タイプ別セグメント分析（増強療法、嚢胞性線維症（CF）、非CF気管支拡張症（NCFB）、糖尿病、その他）、用途別セグメント分析（病院、専門クリニック、薬局）、地域別市場規模、主要企業のプロファイルなどに関する情報を掲載しています。主要企業としては、Pfizer、GlaxoSmithKline、AstraZeneca、Boehringer Ingelheim、Teva Pharmaceutical Industries、Takeda、Baxter、Grifols、CSL Behring、Kamada Ltd、Chiesi Pharmaceuticals、Kedrion Group、Vertex Pharmaceuticals、ProMetic Life Sciencesなどが含まれています。α-1治療のグローバル市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。新型コロナとロシア・ウクライナ戦争の影響は、α-1治療市場規模を算出する際に考慮しました。

・α-1治療市場の概要
- α-1治療の種類別セグメント
- 世界のα-1治療市場規模：タイプ別分析（増強療法、嚢胞性線維症（CF）、非CF気管支拡張症（NCFB）、糖尿病、その他）
- α-1治療の用途別セグメント
- 世界のα-1治療市場規模：用途別分析（病院、専門クリニック、薬局）
- 世界のα-1治療市場規模予測（2018年-2029年）

・α-1治療市場の成長トレンド
- α-1治療の地域別市場規模（2018年-2029年）
- α-1治療市場ダイナミクス
- α-1治療の業界動向
- α-1治療市場の成長ドライバ、課題、阻害要因

・主要企業別競争状況
- 企業別市場シェア
- 世界の主要企業、業界ランキング分析
- 市場への参入、M＆A動向

・種類別セグメント：増強療法、嚢胞性線維症（CF）、非CF気管支拡張症（NCFB）、糖尿病、その他
- 世界のα-1治療のタイプ別市場規模（2018年-2023年）
- 世界のα-1治療のタイプ別市場規模（2024年-2029年）

・用途別セグメント：病院、専門クリニック、薬局
- 世界のα-1治療の用途別市場規模（2018年-2023年）
- 世界のα-1治療の用途別市場規模（2024年-2029年）

・α-1治療の地域別市場規模
- 北米のα-1治療市場規模（2018年-2029年）
- 米国のα-1治療市場規模（2018年-2029年）
- ヨーロッパのα-1治療市場規模（2018年-2029年）
- アジア太平洋のα-1治療市場規模（2018年-2029年）
- 中国のα-1治療市場規模（2018年-2029年）
- 日本のα-1治療市場規模（2018年-2029年）
- 韓国のα-1治療市場規模（2018年-2029年）
- インドのα-1治療市場規模（2018年-2029年）
- オーストラリアのα-1治療市場規模（2018年-2029年）
- 中南米のα-1治療市場規模（2018年-2029年）
- 中東・アフリカのα-1治療市場規模（2018年-2029年）

・主要企業のプロファイル：企業情報、事業概要、売上、動向
Pfizer、GlaxoSmithKline、AstraZeneca、Boehringer Ingelheim、Teva Pharmaceutical Industries、Takeda、Baxter、Grifols、CSL Behring、Kamada Ltd、Chiesi Pharmaceuticals、Kedrion Group、Vertex Pharmaceuticals、ProMetic Life Sciences

・アナリストの観点/結論

・調査手法と情報源

Highlights
The global Treatments for Alpha-1 market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Treatments for Alpha-1 is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Treatments for Alpha-1 is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Treatments for Alpha-1 in Hospitals is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Treatments for Alpha-1 include Pfizer, GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Teva Pharmaceutical Industries, Takeda, Baxter, Grifols and CSL Behring, etc. In 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Treatments for Alpha-1, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Treatments for Alpha-1.
The Treatments for Alpha-1 market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Treatments for Alpha-1 market comprehensively. Regional market sizes, concerning products by indication, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Treatments for Alpha-1 companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by indication, by application, and by regions.
By Company
Pfizer
GlaxoSmithKline
AstraZeneca
Boehringer Ingelheim
Teva Pharmaceutical Industries
Takeda
Baxter
Grifols
CSL Behring
Kamada Ltd
Chiesi Pharmaceuticals
Kedrion Group
Vertex Pharmaceuticals
ProMetic Life Sciences
Segment by Indication
Augmentation Therapy
Cystic Fibrosis(CF)
Non-CF Bronchiectasis(NCFB)
Diabetes
Other
Segment by Application
Hospitals
Specialty Clinics
Pharmacies
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by indication, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Treatments for Alpha-1 companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by indication, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

*** レポート目次（コンテンツ）***

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Indication
1.2.1 Global Treatments for Alpha-1 Market Size Growth Rate by Indication: 2018 VS 2022 VS 2029
1.2.2 Augmentation Therapy
1.2.3 Cystic Fibrosis(CF)
1.2.4 Non-CF Bronchiectasis(NCFB)
1.2.5 Diabetes
1.2.6 Other
1.3 Market by Application
1.3.1 Global Treatments for Alpha-1 Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospitals
1.3.3 Specialty Clinics
1.3.4 Pharmacies
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Treatments for Alpha-1 Market Perspective (2018-2029)
2.2 Treatments for Alpha-1 Growth Trends by Region
2.2.1 Global Treatments for Alpha-1 Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Treatments for Alpha-1 Historic Market Size by Region (2018-2023)
2.2.3 Treatments for Alpha-1 Forecasted Market Size by Region (2024-2029)
2.3 Treatments for Alpha-1 Market Dynamics
2.3.1 Treatments for Alpha-1 Industry Trends
2.3.2 Treatments for Alpha-1 Market Drivers
2.3.3 Treatments for Alpha-1 Market Challenges
2.3.4 Treatments for Alpha-1 Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Treatments for Alpha-1 Players by Revenue
3.1.1 Global Top Treatments for Alpha-1 Players by Revenue (2018-2023)
3.1.2 Global Treatments for Alpha-1 Revenue Market Share by Players (2018-2023)
3.2 Global Treatments for Alpha-1 Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Treatments for Alpha-1 Revenue
3.4 Global Treatments for Alpha-1 Market Concentration Ratio
3.4.1 Global Treatments for Alpha-1 Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Treatments for Alpha-1 Revenue in 2022
3.5 Treatments for Alpha-1 Key Players Head office and Area Served
3.6 Key Players Treatments for Alpha-1 Product Solution and Service
3.7 Date of Enter into Treatments for Alpha-1 Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Treatments for Alpha-1 Breakdown Data by Indication
4.1 Global Treatments for Alpha-1 Historic Market Size by Indication (2018-2023)
4.2 Global Treatments for Alpha-1 Forecasted Market Size by Indication (2024-2029)
5 Treatments for Alpha-1 Breakdown Data by Application
5.1 Global Treatments for Alpha-1 Historic Market Size by Application (2018-2023)
5.2 Global Treatments for Alpha-1 Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Treatments for Alpha-1 Market Size (2018-2029)
6.2 North America Treatments for Alpha-1 Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Treatments for Alpha-1 Market Size by Country (2018-2023)
6.4 North America Treatments for Alpha-1 Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Treatments for Alpha-1 Market Size (2018-2029)
7.2 Europe Treatments for Alpha-1 Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Treatments for Alpha-1 Market Size by Country (2018-2023)
7.4 Europe Treatments for Alpha-1 Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Treatments for Alpha-1 Market Size (2018-2029)
8.2 Asia-Pacific Treatments for Alpha-1 Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Treatments for Alpha-1 Market Size by Region (2018-2023)
8.4 Asia-Pacific Treatments for Alpha-1 Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Treatments for Alpha-1 Market Size (2018-2029)
9.2 Latin America Treatments for Alpha-1 Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Treatments for Alpha-1 Market Size by Country (2018-2023)
9.4 Latin America Treatments for Alpha-1 Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Treatments for Alpha-1 Market Size (2018-2029)
10.2 Middle East & Africa Treatments for Alpha-1 Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Treatments for Alpha-1 Market Size by Country (2018-2023)
10.4 Middle East & Africa Treatments for Alpha-1 Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Detail
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Treatments for Alpha-1 Introduction
11.1.4 Pfizer Revenue in Treatments for Alpha-1 Business (2018-2023)
11.1.5 Pfizer Recent Development
11.2 GlaxoSmithKline
11.2.1 GlaxoSmithKline Company Detail
11.2.2 GlaxoSmithKline Business Overview
11.2.3 GlaxoSmithKline Treatments for Alpha-1 Introduction
11.2.4 GlaxoSmithKline Revenue in Treatments for Alpha-1 Business (2018-2023)
11.2.5 GlaxoSmithKline Recent Development
11.3 AstraZeneca
11.3.1 AstraZeneca Company Detail
11.3.2 AstraZeneca Business Overview
11.3.3 AstraZeneca Treatments for Alpha-1 Introduction
11.3.4 AstraZeneca Revenue in Treatments for Alpha-1 Business (2018-2023)
11.3.5 AstraZeneca Recent Development
11.4 Boehringer Ingelheim
11.4.1 Boehringer Ingelheim Company Detail
11.4.2 Boehringer Ingelheim Business Overview
11.4.3 Boehringer Ingelheim Treatments for Alpha-1 Introduction
11.4.4 Boehringer Ingelheim Revenue in Treatments for Alpha-1 Business (2018-2023)
11.4.5 Boehringer Ingelheim Recent Development
11.5 Teva Pharmaceutical Industries
11.5.1 Teva Pharmaceutical Industries Company Detail
11.5.2 Teva Pharmaceutical Industries Business Overview
11.5.3 Teva Pharmaceutical Industries Treatments for Alpha-1 Introduction
11.5.4 Teva Pharmaceutical Industries Revenue in Treatments for Alpha-1 Business (2018-2023)
11.5.5 Teva Pharmaceutical Industries Recent Development
11.6 Takeda
11.6.1 Takeda Company Detail
11.6.2 Takeda Business Overview
11.6.3 Takeda Treatments for Alpha-1 Introduction
11.6.4 Takeda Revenue in Treatments for Alpha-1 Business (2018-2023)
11.6.5 Takeda Recent Development
11.7 Baxter
11.7.1 Baxter Company Detail
11.7.2 Baxter Business Overview
11.7.3 Baxter Treatments for Alpha-1 Introduction
11.7.4 Baxter Revenue in Treatments for Alpha-1 Business (2018-2023)
11.7.5 Baxter Recent Development
11.8 Grifols
11.8.1 Grifols Company Detail
11.8.2 Grifols Business Overview
11.8.3 Grifols Treatments for Alpha-1 Introduction
11.8.4 Grifols Revenue in Treatments for Alpha-1 Business (2018-2023)
11.8.5 Grifols Recent Development
11.9 CSL Behring
11.9.1 CSL Behring Company Detail
11.9.2 CSL Behring Business Overview
11.9.3 CSL Behring Treatments for Alpha-1 Introduction
11.9.4 CSL Behring Revenue in Treatments for Alpha-1 Business (2018-2023)
11.9.5 CSL Behring Recent Development
11.10 Kamada Ltd
11.10.1 Kamada Ltd Company Detail
11.10.2 Kamada Ltd Business Overview
11.10.3 Kamada Ltd Treatments for Alpha-1 Introduction
11.10.4 Kamada Ltd Revenue in Treatments for Alpha-1 Business (2018-2023)
11.10.5 Kamada Ltd Recent Development
11.11 Chiesi Pharmaceuticals
11.11.1 Chiesi Pharmaceuticals Company Detail
11.11.2 Chiesi Pharmaceuticals Business Overview
11.11.3 Chiesi Pharmaceuticals Treatments for Alpha-1 Introduction
11.11.4 Chiesi Pharmaceuticals Revenue in Treatments for Alpha-1 Business (2018-2023)
11.11.5 Chiesi Pharmaceuticals Recent Development
11.12 Kedrion Group
11.12.1 Kedrion Group Company Detail
11.12.2 Kedrion Group Business Overview
11.12.3 Kedrion Group Treatments for Alpha-1 Introduction
11.12.4 Kedrion Group Revenue in Treatments for Alpha-1 Business (2018-2023)
11.12.5 Kedrion Group Recent Development
11.13 Vertex Pharmaceuticals
11.13.1 Vertex Pharmaceuticals Company Detail
11.13.2 Vertex Pharmaceuticals Business Overview
11.13.3 Vertex Pharmaceuticals Treatments for Alpha-1 Introduction
11.13.4 Vertex Pharmaceuticals Revenue in Treatments for Alpha-1 Business (2018-2023)
11.13.5 Vertex Pharmaceuticals Recent Development
11.14 ProMetic Life Sciences
11.14.1 ProMetic Life Sciences Company Detail
11.14.2 ProMetic Life Sciences Business Overview
11.14.3 ProMetic Life Sciences Treatments for Alpha-1 Introduction
11.14.4 ProMetic Life Sciences Revenue in Treatments for Alpha-1 Business (2018-2023)
11.14.5 ProMetic Life Sciences Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Treatments for Alpha-1 Market Size Growth Rate by Indication (US$ Million): 2018 VS 2022 VS 2029
Table 2. Key Players of Augmentation Therapy
Table 3. Key Players of Cystic Fibrosis(CF)
Table 4. Key Players of Non-CF Bronchiectasis(NCFB)
Table 5. Key Players of Diabetes
Table 6. Key Players of Other
Table 7. Global Treatments for Alpha-1 Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029
Table 8. Global Treatments for Alpha-1 Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 9. Global Treatments for Alpha-1 Market Size by Region (2018-2023) & (US$ Million)
Table 10. Global Treatments for Alpha-1 Market Share by Region (2018-2023)
Table 11. Global Treatments for Alpha-1 Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 12. Global Treatments for Alpha-1 Market Share by Region (2024-2029)
Table 13. Treatments for Alpha-1 Market Trends
Table 14. Treatments for Alpha-1 Market Drivers
Table 15. Treatments for Alpha-1 Market Challenges
Table 16. Treatments for Alpha-1 Market Restraints
Table 17. Global Treatments for Alpha-1 Revenue by Players (2018-2023) & (US$ Million)
Table 18. Global Treatments for Alpha-1 Market Share by Players (2018-2023)
Table 19. Global Top Treatments for Alpha-1 Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Treatments for Alpha-1 as of 2022)
Table 20. Ranking of Global Top Treatments for Alpha-1 Companies by Revenue (US$ Million) in 2022
Table 21. Global 5 Largest Players Market Share by Treatments for Alpha-1 Revenue (CR5 and HHI) & (2018-2023)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Treatments for Alpha-1 Product Solution and Service
Table 24. Date of Enter into Treatments for Alpha-1 Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Treatments for Alpha-1 Market Size by Indication (2018-2023) & (US$ Million)
Table 27. Global Treatments for Alpha-1 Revenue Market Share by Indication (2018-2023)
Table 28. Global Treatments for Alpha-1 Forecasted Market Size by Indication (2024-2029) & (US$ Million)
Table 29. Global Treatments for Alpha-1 Revenue Market Share by Indication (2024-2029)
Table 30. Global Treatments for Alpha-1 Market Size by Application (2018-2023) & (US$ Million)
Table 31. Global Treatments for Alpha-1 Revenue Market Share by Application (2018-2023)
Table 32. Global Treatments for Alpha-1 Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 33. Global Treatments for Alpha-1 Revenue Market Share by Application (2024-2029)
Table 34. North America Treatments for Alpha-1 Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 35. North America Treatments for Alpha-1 Market Size by Country (2018-2023) & (US$ Million)
Table 36. North America Treatments for Alpha-1 Market Size by Country (2024-2029) & (US$ Million)
Table 37. Europe Treatments for Alpha-1 Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 38. Europe Treatments for Alpha-1 Market Size by Country (2018-2023) & (US$ Million)
Table 39. Europe Treatments for Alpha-1 Market Size by Country (2024-2029) & (US$ Million)
Table 40. Asia-Pacific Treatments for Alpha-1 Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029
Table 41. Asia-Pacific Treatments for Alpha-1 Market Size by Region (2018-2023) & (US$ Million)
Table 42. Asia-Pacific Treatments for Alpha-1 Market Size by Region (2024-2029) & (US$ Million)
Table 43. Latin America Treatments for Alpha-1 Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 44. Latin America Treatments for Alpha-1 Market Size by Country (2018-2023) & (US$ Million)
Table 45. Latin America Treatments for Alpha-1 Market Size by Country (2024-2029) & (US$ Million)
Table 46. Middle East & Africa Treatments for Alpha-1 Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 47. Middle East & Africa Treatments for Alpha-1 Market Size by Country (2018-2023) & (US$ Million)
Table 48. Middle East & Africa Treatments for Alpha-1 Market Size by Country (2024-2029) & (US$ Million)
Table 49. Pfizer Company Detail
Table 50. Pfizer Business Overview
Table 51. Pfizer Treatments for Alpha-1 Product
Table 52. Pfizer Revenue in Treatments for Alpha-1 Business (2018-2023) & (US$ Million)
Table 53. Pfizer Recent Development
Table 54. GlaxoSmithKline Company Detail
Table 55. GlaxoSmithKline Business Overview
Table 56. GlaxoSmithKline Treatments for Alpha-1 Product
Table 57. GlaxoSmithKline Revenue in Treatments for Alpha-1 Business (2018-2023) & (US$ Million)
Table 58. GlaxoSmithKline Recent Development
Table 59. AstraZeneca Company Detail
Table 60. AstraZeneca Business Overview
Table 61. AstraZeneca Treatments for Alpha-1 Product
Table 62. AstraZeneca Revenue in Treatments for Alpha-1 Business (2018-2023) & (US$ Million)
Table 63. AstraZeneca Recent Development
Table 64. Boehringer Ingelheim Company Detail
Table 65. Boehringer Ingelheim Business Overview
Table 66. Boehringer Ingelheim Treatments for Alpha-1 Product
Table 67. Boehringer Ingelheim Revenue in Treatments for Alpha-1 Business (2018-2023) & (US$ Million)
Table 68. Boehringer Ingelheim Recent Development
Table 69. Teva Pharmaceutical Industries Company Detail
Table 70. Teva Pharmaceutical Industries Business Overview
Table 71. Teva Pharmaceutical Industries Treatments for Alpha-1 Product
Table 72. Teva Pharmaceutical Industries Revenue in Treatments for Alpha-1 Business (2018-2023) & (US$ Million)
Table 73. Teva Pharmaceutical Industries Recent Development
Table 74. Takeda Company Detail
Table 75. Takeda Business Overview
Table 76. Takeda Treatments for Alpha-1 Product
Table 77. Takeda Revenue in Treatments for Alpha-1 Business (2018-2023) & (US$ Million)
Table 78. Takeda Recent Development
Table 79. Baxter Company Detail
Table 80. Baxter Business Overview
Table 81. Baxter Treatments for Alpha-1 Product
Table 82. Baxter Revenue in Treatments for Alpha-1 Business (2018-2023) & (US$ Million)
Table 83. Baxter Recent Development
Table 84. Grifols Company Detail
Table 85. Grifols Business Overview
Table 86. Grifols Treatments for Alpha-1 Product
Table 87. Grifols Revenue in Treatments for Alpha-1 Business (2018-2023) & (US$ Million)
Table 88. Grifols Recent Development
Table 89. CSL Behring Company Detail
Table 90. CSL Behring Business Overview
Table 91. CSL Behring Treatments for Alpha-1 Product
Table 92. CSL Behring Revenue in Treatments for Alpha-1 Business (2018-2023) & (US$ Million)
Table 93. CSL Behring Recent Development
Table 94. Kamada Ltd Company Detail
Table 95. Kamada Ltd Business Overview
Table 96. Kamada Ltd Treatments for Alpha-1 Product
Table 97. Kamada Ltd Revenue in Treatments for Alpha-1 Business (2018-2023) & (US$ Million)
Table 98. Kamada Ltd Recent Development
Table 99. Chiesi Pharmaceuticals Company Detail
Table 100. Chiesi Pharmaceuticals Business Overview
Table 101. Chiesi Pharmaceuticals Treatments for Alpha-1 Product
Table 102. Chiesi Pharmaceuticals Revenue in Treatments for Alpha-1 Business (2018-2023) & (US$ Million)
Table 103. Chiesi Pharmaceuticals Recent Development
Table 104. Kedrion Group Company Detail
Table 105. Kedrion Group Business Overview
Table 106. Kedrion Group Treatments for Alpha-1 Product
Table 107. Kedrion Group Revenue in Treatments for Alpha-1 Business (2018-2023) & (US$ Million)
Table 108. Kedrion Group Recent Development
Table 109. Vertex Pharmaceuticals Company Detail
Table 110. Vertex Pharmaceuticals Business Overview
Table 111. Vertex Pharmaceuticals Treatments for Alpha-1 Product
Table 112. Vertex Pharmaceuticals Revenue in Treatments for Alpha-1 Business (2018-2023) & (US$ Million)
Table 113. Vertex Pharmaceuticals Recent Development
Table 114. ProMetic Life Sciences Company Detail
Table 115. ProMetic Life Sciences Business Overview
Table 116. ProMetic Life Sciences Treatments for Alpha-1 Product
Table 117. ProMetic Life Sciences Revenue in Treatments for Alpha-1 Business (2018-2023) & (US$ Million)
Table 118. ProMetic Life Sciences Recent Development
Table 119. Research Programs/Design for This Report
Table 120. Key Data Information from Secondary Sources
Table 121. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Treatments for Alpha-1 Market Size Comparison by Indication (2023-2029) & (US$ Million)
Figure 2. Global Treatments for Alpha-1 Market Share by Indication: 2022 VS 2029
Figure 3. Augmentation Therapy Features
Figure 4. Cystic Fibrosis(CF) Features
Figure 5. Non-CF Bronchiectasis(NCFB) Features
Figure 6. Diabetes Features
Figure 7. Other Features
Figure 8. Global Treatments for Alpha-1 Market Size Comparison by Application (2023-2029) & (US$ Million)
Figure 9. Global Treatments for Alpha-1 Market Share by Application: 2022 VS 2029
Figure 10. Hospitals Case Studies
Figure 11. Specialty Clinics Case Studies
Figure 12. Pharmacies Case Studies
Figure 13. Treatments for Alpha-1 Report Years Considered
Figure 14. Global Treatments for Alpha-1 Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 15. Global Treatments for Alpha-1 Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 16. Global Treatments for Alpha-1 Market Share by Region: 2022 VS 2029
Figure 17. Global Treatments for Alpha-1 Market Share by Players in 2022
Figure 18. Global Top Treatments for Alpha-1 Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Treatments for Alpha-1 as of 2022)
Figure 19. The Top 10 and 5 Players Market Share by Treatments for Alpha-1 Revenue in 2022
Figure 20. North America Treatments for Alpha-1 Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 21. North America Treatments for Alpha-1 Market Share by Country (2018-2029)
Figure 22. United States Treatments for Alpha-1 Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 23. Canada Treatments for Alpha-1 Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 24. Europe Treatments for Alpha-1 Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 25. Europe Treatments for Alpha-1 Market Share by Country (2018-2029)
Figure 26. Germany Treatments for Alpha-1 Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 27. France Treatments for Alpha-1 Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 28. U.K. Treatments for Alpha-1 Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 29. Italy Treatments for Alpha-1 Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. Russia Treatments for Alpha-1 Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. Nordic Countries Treatments for Alpha-1 Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. Asia-Pacific Treatments for Alpha-1 Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. Asia-Pacific Treatments for Alpha-1 Market Share by Region (2018-2029)
Figure 34. China Treatments for Alpha-1 Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. Japan Treatments for Alpha-1 Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. South Korea Treatments for Alpha-1 Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 37. Southeast Asia Treatments for Alpha-1 Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 38. India Treatments for Alpha-1 Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 39. Australia Treatments for Alpha-1 Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 40. Latin America Treatments for Alpha-1 Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 41. Latin America Treatments for Alpha-1 Market Share by Country (2018-2029)
Figure 42. Mexico Treatments for Alpha-1 Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 43. Brazil Treatments for Alpha-1 Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 44. Middle East & Africa Treatments for Alpha-1 Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. Middle East & Africa Treatments for Alpha-1 Market Share by Country (2018-2029)
Figure 46. Turkey Treatments for Alpha-1 Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 47. Saudi Arabia Treatments for Alpha-1 Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 48. Pfizer Revenue Growth Rate in Treatments for Alpha-1 Business (2018-2023)
Figure 49. GlaxoSmithKline Revenue Growth Rate in Treatments for Alpha-1 Business (2018-2023)
Figure 50. AstraZeneca Revenue Growth Rate in Treatments for Alpha-1 Business (2018-2023)
Figure 51. Boehringer Ingelheim Revenue Growth Rate in Treatments for Alpha-1 Business (2018-2023)
Figure 52. Teva Pharmaceutical Industries Revenue Growth Rate in Treatments for Alpha-1 Business (2018-2023)
Figure 53. Takeda Revenue Growth Rate in Treatments for Alpha-1 Business (2018-2023)
Figure 54. Baxter Revenue Growth Rate in Treatments for Alpha-1 Business (2018-2023)
Figure 55. Grifols Revenue Growth Rate in Treatments for Alpha-1 Business (2018-2023)
Figure 56. CSL Behring Revenue Growth Rate in Treatments for Alpha-1 Business (2018-2023)
Figure 57. Kamada Ltd Revenue Growth Rate in Treatments for Alpha-1 Business (2018-2023)
Figure 58. Chiesi Pharmaceuticals Revenue Growth Rate in Treatments for Alpha-1 Business (2018-2023)
Figure 59. Kedrion Group Revenue Growth Rate in Treatments for Alpha-1 Business (2018-2023)
Figure 60. Vertex Pharmaceuticals Revenue Growth Rate in Treatments for Alpha-1 Business (2018-2023)
Figure 61. ProMetic Life Sciences Revenue Growth Rate in Treatments for Alpha-1 Business (2018-2023)
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed


*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 潰瘍性大腸炎治療オプションの世界市場2023年：抗炎症薬、免疫抑制剤、その他医薬品
  • アドレナリン受容体遮断薬の世界市場2023年：アルファブロッカー、ベータブロッカー、その他
  • トリメチルアミン尿症治療の世界市場2023年：経口、注射
  • 犬におけるレプトスピラ症治療の世界市場2023年：経口型、静脈注射型
  • 原発性硬化性胆管炎（PSC）の世界市場2023年：医療、肝移植、その他
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(QYR23MA8912 )"α-1治療の世界市場2023年：増強療法、嚢胞性線維症（CF）、非CF気管支拡張症（NCFB）、糖尿病、その他" (英文：Global Treatments for Alpha-1 Market Research Report 2023)はQYResearch社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。